Stephen V Liu: Will HARMONi-A Redefine 2L EGFR NSCLC Therapy?
Stephen V Liu, Director of Thoracic Oncology, Chief, Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X about a paper
“Akeso reports Phase III HARMONi-A trial positive for survival.
Ivonescimab (PD1/VEGF bispecific) + chemotherapy vs chemo in EGFR NSCLC post TKI already showed PFS benefit (7.1m vs 4.8m), but OS was in question. Full results to be presented at WCLC25.
How does this influence first-line choices?
FLAURA2 (osimertinib plus chemo) will be updated at WCLC25, showing an OS benefit over osi.
MARIPOSA (amivantamab + lazertinib) also showed an OS benefit over osi.
Will we want to avoid 1L chemo if HARMONi-A becomes the 2L standard? Depends on all of the details, the magnitude of the benefit. Stay tuned for WCLC25 from Barcelona!”
More posts featuring Stephen V Liu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023